Jaber, Samir
Quintard, Hervé
Cinotti, Raphael
Asehnoune, Karim
Arnal, Jean-Michel
Guitton, Christophe
Paugam-Burtz, Catherine
Abback, Paer
Mekontso Dessap, Armand
Lakhal, Karim
Lasocki, Sigismond
Plantefeve, Gaetan
Claud, Bernard
Pottecher, Julien
Corne, Philippe
Ichai, Carole
Hajjej, Zied
Molinari, Nicolas
Chanques, Gerald
Papazian, Laurent
Azoulay, Elie
De Jong, Audrey
Article History
Received: 7 June 2018
Accepted: 7 August 2018
First Online: 23 September 2018
Ethics approval and consent to participate
: The appropriate IRB (<i>Comité de Protection des personnes Sud-Mediterranée III</i>) approved the study protocol (code UF: 9242, register: 2013-A01402–43), and, based on the observational design, waived the need for written informed consent. Next of kin were informed of the study, as were patients as soon as their neurologic status was deemed adequate. Written information was delivered to the patient’s next of kin and to the patient when neurologic recovery was deemed appropriate. The study was registered on ClinicalTrials.gov (identifier number NCT 02450669).
: Not applicable.
: Pr Jaber reports receiving consulting fees from Drager, Hamilton, Maquet and Fisher & Paykel.Elie Azoulay has received fees from Gilead Sciences, Alexion, Astellas, MSD and Drager.Julien Pottecher has received fees from Medtronic, Baxter and Getinge. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.